
Positive Phase 3 survival data cannot justify a $3.9bn valuation; initiate at Sell
We initiate on SELLAS Life Sciences at Sell with an $8.77 12-month target, or −54.2% total return from $19.15. SELLAS develops licensed oncology drugs led by galinpepimut-S (GPS) for acute myeloid leukaemia (AML). Shares jumped 156% after Phase 3 REGAL met overall survival (OS) in second complete remission (CR2). We value clinical assets by risk-adjusted net present value (rNPV), multiplying discounted cash flows by approval odds.
- Even 100% CR2 approval odds value SLS at $6.36 per share. About 1,700 unfit US adults enter CR2 yearly, capping approval-case US CR2 sales at $418m.
- One open-label trial warrants 65% CR2 odds, worth $3.03 per share. REGAL enrolled 126 patients (p=0.035) with undisclosed confidence intervals (CI) ahead of Food and Drug Administration (FDA) review.
- Launch and trial spend lifts FY27E net loss to $101m before FY28E equity needs. Funding Biologics License Application (BLA) work, first complete remission (CR1) Phase 3 and tambiciclib (SLS009) requires a further $37m of equity after the November offering.
What the market is missing. Reverse rNPV shows $19.15 implies $4.9bn of peak US GPS sales, or 3.4x our $1.4bn CR2-plus-CR1 forecast. Consensus models $53m of FY27E sales, yet H1 27 BLA timing makes FY27E sales unlikely; we assume H1 2028 approval.
Catalysts. American Society of Hematology (ASH) data arrive in December 2026, with full REGAL curves in Dec 26–H1 27. FDA pre-BLA feedback, H1 27 filing and $150m deal terms follow.
Valuation and target. Base rNPV at an 11.1% cost of equity is $4.97/sh, cross-checked at $4.11 via a 2.3x FY30E peer sales exit. Weighting Bear ($0.18, 30%), Base ($4.97, 50%) and Bull ($26.77, 20%) gives $7.90 today and an $8.77 target.
Risks. Upside risks to Sell include CR1 Phase 3 alignment (+$0.36/sh indicative), 60% CR2 uptake (+$0.58/sh indicative) and $450k pricing.
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Risk-adj. revenue | 0.0 | 0.0 | 0.0 | 0.0 | 19.0 |
| Approval-case CR2 rev. | 0.0 | 0.0 | 0.0 | 0.0 | 29.3 |
| EBITDA (risk-adj.) | (31.5) | (28.3) | (45.2) | (110.2) | (97.2) |
| Operating costs | (31.5) | (28.3) | (45.2) | (110.2) | (116.2) |
| Net income | (30.9) | (26.9) | (40.9) | (101.0) | (91.5) |
| Diluted EPS ($) | (0.50) | (0.25) | (0.19) | (0.48) | (0.43) |
| Free cash flow (FCF) | (35.4) | (28.4) | (35.2) | (101.0) | (94.4) |
| Closing cash | 13.9 | 71.8 | 262.1 | 161.1 | 75.0 |
| At $19.15, 17 Nov | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| EV / risk-adj. sales | n.m. | n.m. | n.m. | n.m. | 197.7x |
| Price / earnings (P/E) | n.m. | n.m. | n.m. | n.m. | n.m. |
| Price / cash per share | 84.4x | 29.1x | 15.5x | 25.2x | 54.6x |
| FCF yield | −3.0% | −1.4% | −0.9% | −2.5% | −2.3% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cash per share ($) | 0.23 | 0.66 | 1.23 | 0.76 | 0.35 |
| Cash runway (mos) | 5.9 | 24.5 | 31.1 | 20.5 | floor |
| Target EV / FY30E rev. | n.a. | n.a. | 10.1x | 10.1x | 10.1x |
Source: US Securities and Exchange Commission (SEC) filings (A); Penmark Research model (E, 19 Nov 2026). Earnings before interest, tax, depreciation & amortisation (EBITDA); earnings per share (EPS).
Base rNPV is $4.97 per share; bull upside is 0.40 times bear downside
Source: Yahoo Finance; Penmark Research model. Fan endpoints roll present values ($26.77, $4.97, $0.18; weighted $7.90) forward 12 months at 11.1% Ke.
| Bull (20%) | $26.77 | +39.8% today (+55.2% 12m); 85% CR2 odds, $450k price, 70% CR2 uptake, 50% CR1 odds. |
| Base (50%) | $4.97 | −74.0% today (−71.2% 12m); 65% CR2 odds, $300k price, 45% CR2 uptake, FY28E launch. |
| Bear (30%) | $0.18 | −99.0% today (−98.9% 12m); confirmatory study cuts CR2 odds to 40%, launch FY29E. |
| 12m Target | $8.77 | −54.2% total return → Sell (weighted $7.90/sh rolled 12m at 11.1% Ke; 0.0% dividend). |
Price target basis: Sum-of-programmes rNPV across GPS CR2 ($3.03/sh), GPS CR1 ($2.49/sh) and SLS009 ($0.39/sh), less corporate costs (−$1.02/sh) and post-net operating loss (NOL) tax (−$1.23/sh), plus net cash, offering and future raises ($1.31/sh) on 230.9m diluted shares. Bull upside from $19.15 (+$7.62) is 0.40 times downside to our $0.18 bear case (−$18.97). Cross-checked at $4.11/sh via 2.3x FY30E peer sales.
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Risk-adj. revenue | 0.0 | 0.0 | 0.0 | 0.0 | 19.0 |
| Approval-case CR2 rev. | 0.0 | 0.0 | 0.0 | 0.0 | 29.3 |
| R&D & clinical costs | (19.1) | (16.0) | (27.4) | (70.2) | (63.3) |
| COGS, comm. & G&A | (12.4) | (12.3) | (17.8) | (40.0) | (52.9) |
| EBITDA (risk-adj.) | (31.5) | (28.3) | (45.2) | (110.2) | (97.2) |
| Net interest / other | 0.6 | 1.4 | 4.3 | 9.2 | 5.6 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | (30.9) | (26.9) | (40.9) | (101.0) | (91.5) |
Source: SEC filings (A); Penmark Research model (E). Research & development (R&D); cost of goods sold (COGS); general & administrative (G&A).
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Operating cash flow | (35.4) | (28.4) | (35.2) | (101.0) | (94.4) |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow (FCF) | (35.4) | (28.4) | (35.2) | (101.0) | (94.4) |
| Equity & warrant inflows | 46.8 | 86.3 | 85.3 | 0.0 | 0.0 |
| Nov 2026 offering (net) | 0.0 | 0.0 | 140.3 | 0.0 | 0.0 |
| Future equity raised | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 |
| Net change in cash | 11.4 | 57.9 | 190.3 | (101.0) | (86.1) |
Source: SEC filings (A); Penmark Research model (E; FY26E sums unrounded).
| Dec YE, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Opening cash | 2.5 | 13.9 | 71.8 | 262.1 | 161.1 |
| Closing cash & equiv. | 13.9 | 71.8 | 262.1 | 161.1 | 75.0 |
| Total debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net cash | 13.9 | 71.8 | 262.1 | 161.1 | 75.0 |
| Minimum cash floor | n.a. | n.a. | 75.0 | 75.0 | 75.0 |
| Federal NOL closing | n.a. | 77.7 | 119.8 | 230.0 | 327.2 |
| Unused ATM capacity | n.a. | n.a. | 150.0 | 150.0 | 150.0 |
| Unvalued 3D milestones | n.a. | 191.5 | 191.5 | 191.5 | 191.5 |
Source: SEC filings (A; at-the-market, ATM, facility entered Mar 2026); Penmark Research model (E).
| Dec YE | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Shares (wtd A / YE E, m) | 61.2 | 109.1 | 212.4 | 212.4 | 213.8 |
| rNPV diluted shares (m) | n.a. | n.a. | 230.9 | 230.9 | 230.9 |
| Diluted EPS ($) | (0.50) | (0.25) | (0.19) | (0.48) | (0.43) |
| FCF per share ($) | (0.58) | (0.26) | (0.17) | (0.48) | (0.44) |
| Cash per share ($) | 0.23 | 0.66 | 1.23 | 0.76 | 0.35 |
| Pre-equity runway (mos) | 5.9 | 24.5 | 31.1 | 20.5 | floor |
| CR2 US pt-yrs (unrisked) | 0 | 0 | 0 | 0 | 98 |
| Active Phase 2/3 studies | 4 | 4 | 5 | 5 | 4 |
Source: SEC filings (A); Penmark Research model (E; runway = closing cash / next-year FCF burn).
Modelled FY27E loss of $101.0m is 3.9x consensus as FY27E sales look unlikely
| Metric | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Operating spend & growth | |||||
| Opex growth y/y | −16.8% | −10.3% | +59.8% | +143.9% | +5.4% |
| R&D & clinical share | 60.6% | 56.7% | 60.7% | 63.7% | 54.5% |
| Comm. & G&A share | 39.4% | 43.3% | 39.3% | 36.3% | 45.5% |
| Net loss growth | −17.3% | −13.0% | +52.3% | +146.9% | −9.4% |
| Pipeline odds & cash yield | |||||
| GPS CR2 odds | n.a. | n.a. | 65.0% | 65.0% | 65.0% |
| GPS CR1 odds | n.a. | n.a. | 30.0% | 30.0% | 30.0% |
| SLS009 odds | n.a. | n.a. | 13.0% | 13.0% | 13.0% |
| FY30E EBITDA mgn | n.a. | n.a. | 21.6% | 21.6% | 21.6% |
| Cash interest yield | 4.6% | 3.3% | 3.5% | 3.5% | 3.5% |
Source: SEC filings (A); Penmark Research model (E).
| At $19.15 | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Liquidity, runway & dilution | |||||
| Net cash ($m) | 13.9 | 71.8 | 262.1 | 161.1 | 75.0 |
| Cash floor / sh ($) | n.a. | n.a. | 1.19 | 1.19 | 1.19 |
| Share count growth | +120.3% | +78.2% | +94.7% | 0.0% | +0.7% |
| Net debt / cash | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Valuation multiples (pipeline basis) | |||||
| EV / risk-adj. sales | n.m. | n.m. | n.m. | n.m. | 197.7x |
| EV / FY30E sales | n.a. | n.a. | 21.8x | 21.8x | 21.8x |
| Price / cash per sh | 84.4x | 29.1x | 15.5x | 25.2x | 54.6x |
| FCF yield | −3.0% | −1.4% | −0.9% | −2.5% | −2.3% |
| Target EV/FY30E | n.a. | n.a. | 10.1x | 10.1x | 10.1x |
Source: SEC filings (A); Penmark Research model (E). P/E and EV/EBITDA are n.m. before FY30E.
| Fixed comparison rows | Revenue ($m; FY28E approval-case shown) | Net income ($m) and FY26E GAAP EPS ($) | ||||||
|---|---|---|---|---|---|---|---|---|
| 4Q26E | FY26E | FY27E | FY28E | 4Q26E NI | FY26E EPS | FY27E NI | FY28E NI | |
| Penmark estimate | 0.0 | 0.0 | 0.0 | 29.3 | (12.8) | (0.19) | (101.0) | (91.5) |
| Consensus | n.a. | 0.0 | 53.0 | 122.0 | n.a. | (0.28) | (26.0) | (4.0) |
| Prior-year period | 0.0 | 0.0 | 0.0 | 0.0 | (7.7) | (0.25) | (40.9) | (101.0) |
| Penmark vs consensus* | n.a. | 0.0% | −100.0% | −76.0% | n.a. | −31.2% | +288.6% | +2,188% |
| Penmark y/y change* | n.m. | n.m. | n.m. | launch | +67.4% | −22.9% | +146.9% | −9.4% |
*Positive % on net income (NI) / generally accepted accounting principles (GAAP) EPS loss columns indicates a wider net loss. Source: Seeking Alpha; Simply Wall St (1 estimate); Penmark Research model (FY28E risk-adjusted revenue $19.0m).
Source: SEC filings (A); Simply Wall St consensus; Penmark Research model (E).
H1 27 BLA timing makes FY27E product sales unlikely; we assume H1 2028 approval. Even if granted an eight-month FDA priority review on an early-2027 submission, late-2027 approval would leave little FY27E revenue, rendering $53.0m of consensus sales stale.
Four concurrent workstreams lift FY27E operating costs to $110.2m. SELLAS must fund $35.2m of BLA, chemistry, manufacturing & controls (CMC) and Memorial Sloan Kettering (MSK) milestones, $20.0m of pre-launch preparation, $30.0m across CR1/SLS009 trials and $25.0m of overhead.
Runway holds 31.1 months before FY28E equity needs. Assumed $140.3m net offering proceeds lift FY26E cash to $262.1m, but keeping a $75.0m floor requires $36.7m of added equity across FY28E–FY29E.
SLS trades at 21.8x FY30E sales against a 2.3x commercial oncology peer median
| Measure (17 Nov 2026) | SLS | Median | Difference |
|---|---|---|---|
| Valuation multiples | |||
| EV / sales (SLS: FY30E) | 21.8x | 2.3x | +826.5% |
| Target EV / FY30E sales | 10.1x | 2.3x | +330.7% |
| EV / current run-rate sales | n.m. | 2.3x | n.m. |
| Market cap / cash & ST inv. | 28.9x | 5.4x | +436% |
| Scale & operating profile | |||
| Enterprise value ($m) | 3,762.8 | 759.8 | +395.2% |
| Market capitalisation ($m) | 3,897.6 | 852.6 | +357.1% |
| Cash & ST investments ($m) | 134.7 | 401.7 | −66.5% |
| Total debt ($m) | 0.0 | 65.1 | −100.0% |
| Run-rate revenue ($m) | 0.0 | 328.4 | −100.0% |
| Sales growth (SLS: FY30E) | +60.3% | +22.0% | +38.3pp |
| Commercial drugs (#) | 0 | 1.0 | −1.0 |
Source: SEC Q3 2026 Form 10-Q filings; Yahoo Finance; Penmark Research model. Peers: SNDX (1.9x), KURA (2.1x), IMCR (2.3x), RIGL (2.4x), GERN (3.0x; EV overstated ex-marketable securities), IOVA (6.3x).
| Timing | Dated event (probability) | Indicative |
|---|---|---|
| Dec 2026 | ASH SLS009 r/r cohorts & frontline Phase 2 data (35%) | +$0.16 |
| Dec 26–H1 27 | Full REGAL survival curves & subgroup splits (40%) | +$0.40 |
| H1 27 | FDA pre-BLA feedback & GPS BLA filing acceptance (30%) | −$0.67 |
| 2027 | GPS CR1 maintenance Phase 3 trial start & alignment (50%) | +$0.36 |
Source: Company releases; Penmark Research model (indicative $/sh impacts).
| Side / prob. | Risk to value or Sell rating | Indicative |
|---|---|---|
| Up (30%) | Upside risk to Sell: Key opinion leaders (KOLs) lift CR2 uptake to 60% | +$0.58 |
| Down (30%) | FDA requires confirmatory trial; CR2 odds cut to 40%, FY29E | −$0.67 |
| Down (30%) | Menin inhibitors & venetoclax shrink CR2 share to 30% | −$0.58 |
| Down (25%) | Payer pushback caps US GPS net price at $200k/yr | −$0.58 |
Source: Penmark Research model (indicative $/sh impacts). Monitoring triggers sit in the catalysts chapter.
Standard deviation (SD) bands show typical variation around the 12-month monthly average (9.1x). The REGAL jump pushed SLS right to +2.0 SD (21.8x).
Source: Yahoo Finance monthly closes; SEC filings; Penmark Research model.
Peer regression (R² = 0.28, n = 6) across the six commercial oncology peers shows revenue growth alone leaves SLS far above the peer line at 21.8x.
Source: SEC Q3 2026 Form 10-Q filings; Yahoo Finance; Penmark Research model.
Current valuation implies 3.4x our peak US GPS sales forecast
REGAL survival headlines triggered a 156.4% jump on 119.9m shares, detaching SLS from pipeline cash flows. Even weighting our $26.77 bull case at 20% yields $7.90 per share today, while $19.15 implies $4,923m of peak US GPS sales.
Clinical catalyst dominance: REGAL event days explain 30.7% of daily return variance (R²) vs 6.4% for XBI.
Source: Yahoo Finance daily closes, Aug to 17 Nov 2026.
Asymmetric downside: Column widths show probabilities; 80% of scenarios sit at or below $4.97 per share.
Source: Penmark Research model.
Epidemiology ceiling: Reproducing $19.15 at base odds requires a 3.44x scalar on treated US AML patients.
Source: Penmark Research reverse-rNPV model.
Stale Street ramp: H1 27 BLA timing makes FY27E sales unlikely; we assume H1 2028 approval ($29.3m unrisked; $19.0m risk-adjusted).
Source: Simply Wall St (1 estimate); Penmark Research model.
Cash floor check: Even adding assumed $140.3m net offering proceeds, the cash floor is $1.19 per diluted share.
Source: Yahoo Finance; SEC Form 10-K and Form 10-Q filings; Penmark Research model.
Source: Maxim ($40), Alliance Global Partners ($35); Penmark Research model.
One-at-a-time market debate concessions sum to $5.43/sh above our $4.97 base
Investors and Penmark disagree on FDA single-trial approval odds, US orphan net pricing, unfit CR2 uptake and CR1 maintenance expansion. Tested one at a time in our full model, conceding each market input adds $0.79 to $1.95 per share ($5.43 summed individually; granting all four together is worth more because price, uptake and approval odds multiply).
| Debate | Market view | Penmark view | Evidence | What changes our view | Resolves |
|---|---|---|---|---|---|
| Orphan net pricing | $400k/yr ($6.92/sh) | $300k/yr ($4.97/sh; −$1.95) | Revuforj lists at $474k wholesale acquisition cost (WAC) pre-rebate; GPS tapers to 6-week dosing after week 52. | ASH payer feedback or launch WAC supporting ≥$400k net per patient-year. | Dec 2026 / FY28E |
| Unfit CR2 uptake | 65% share ($6.57/sh) | 45% share ($4.97/sh; −$1.60) | REGAL control allowed venetoclax / hypomethylating agents (HMA); menin inhibitors trim CR2 pools. | Consistent OS benefit in prior-venetoclax subgroups and Category 1 guideline adoption. | Dec 26–H1 27 |
| CR1 maintenance expansion | 45% odds ($6.06/sh) | 30% odds ($4.97/sh; −$1.09) | Oral azacitidine already holds the CR1 maintenance label; GPS CR1 rests on Phase 2 (n=22) with Phase 3 unstarted. | FDA-aligned CR1 Phase 3 design against oral azacitidine with rapid enrolment. | 2027 |
| Single-trial approval | 85%+ odds ($5.77/sh) | 65% odds ($4.97/sh; −$0.79) | One open-label 126-patient study; two-sided p=0.035; 95% CI undisclosed; events cut from 105 to 80 in 2022. | Consistent OS separation across cytogenetic and venetoclax subgroups, plus FDA waiving a pre-approval trial. | Dec 26–H1 27 |
| One-at-a-time sum | +$5.43/sh | $4.97/sh base | Sum of four separate full-model single-input concessions (conceding all four at once adds more, as price, share and odds multiply). | By H1 2028 | |
Source: Penmark Research model (full-model single-input solves from $4.97/sh base value).
Source: Penmark Research model.
Orphan net pricing and unfit CR2 uptake → CR2 commercial ceiling chapter. Even if GPS wins 65% share ($6.57/sh) or $400k pricing ($6.92/sh) individually, only ~1,700 unfit US adults enter CR2 annually.
Single-trial approval → Regulatory review chapter. REGAL’s 126-patient open-label design and undisclosed confidence interval create a 30% chance FDA requests confirmatory data before approval.
CR1 maintenance expansion → Multi-trial burn & dilution chapter. Reaching the 4.5x larger CR1 pool requires a five-year, $95m Phase 3 study against approved oral azacitidine, launching no earlier than FY32E.
Source: SEC filings and company releases; Penmark Research calendar.
Thirteen staff, zero product sales, and a $3.9bn valuation resting on 1,701 patients a year
SELLAS licenses hospital and cross-border blood-cancer drugs and runs trials that aim to stop acute myeloid leukaemia from returning. Its lead vaccine just extended survival in Phase 3, yet the stock now prices more patients than the disease provides.
On 17 November 2026, nearly 120 million shares of SELLAS Life Sciences changed hands after REGAL reached its 80th event. In 126 older adults whose acute myeloid leukaemia had entered second remission and who could not receive a stem-cell transplant, median survival reached 24.0 months on galinpepimut-S against 14.7 months on standard care. By the closing bell, a thirteen-employee office in Times Square Tower carried a $3.90bn equity value, or $300m per employee, before selling a single commercial vial.
SELLAS discovers no molecules of its own. Instead, it licenses clinical candidates from research centres and biotech partners, hires contract manufacturers and clinical research organisations, and retains US oncology rights. Its lead biologic, GPS, combines four peptides from Memorial Sloan Kettering Cancer Center designed to train T-cells to attack the Wilms tumour 1 (WT1) protein on lingering leukaemia cells while a patient sits in remission. Its second drug, tambiciclib, is an intravenous kinase inhibitor licensed from China’s GenFleet Therapeutics for poor-prognosis leukaemia subsets.
Today no customer pays SELLAS for medicine, so equity and warrant issues fund operations alongside treasury interest. Across 2024 through September 2026, equity and warrant exercises brought in $218.3m to fund $86.2m of operating burn, and management launched an underwritten $150m share offering after the close following the REGAL headline. In our model, product revenue begins in 2028 once specialty distributors buy GPS for US outpatient oncology clinics at $300k net per patient-year (~95% of peak CR2 revenue to SELLAS), while foreign licensees pay a 20% royalty (~5%). By 2035, one dollar of risk-adjusted revenue leaves 52 cents of unlevered programme cash flow (ex-interest) after 10% manufacturing cost, 5% to 6% licensor royalties, field reps, overhead and taxes.
Three moments shaped that model: licensing GPS in September 2014 ahead of the December 2017 Galena reverse merger, paying $10.0m upfront for tambiciclib in March 2022, and pairing November 2026 Phase 3 success with fresh equity. What keeps physicians interested is clear: no approved therapy holds randomised survival proof in unfit second remission. What breaks the stock’s math is equally clear across single-trial approval, orphan net pricing, unfit CR2 uptake and CR1 maintenance expansion: only 1,701 unfit US patients enter second remission yearly, and reaching first remission requires a five-year Phase 3 battle against approved oral azacitidine.
21,000 US adults develop AML yearly; 13.5% reach CR2 and 60% cannot undergo transplant (1,701 eligible).
At 45% peak share, 765 patients start subcutaneous GPS with immune stimulant GM-CSF for 1.25 years.
Specialty distributors and payers pay $300k net per patient-year, or $375k per 1.25-year course at launch.
After 10% COGS, 5% MSK royalty and a $60m US field team, CR2 yields $198.8m unrisked cash flow in FY31E.
Tying the story to the stock: Clinical success in a 1,701-patient niche cannot support a $3.90bn market cap; our scenario-weighted rNPV sets an $8.77 target (−54.2% return, Sell).
Two in-licensed drugs carry 5%–6% royalties and $110.2m of FY27E pre-launch burn
Dr. Stergiou launches predecessor entity to license cancer vaccines (1 founder).
Secures exclusive GPS global rights with up to $17.4m product milestones.
Completes reverse merger on 29 Dec 2017 to list as Nasdaq: SLS.
Out-licenses Greater China GPS rights; $191.5m milestones remain unvalued.
Pays $10.0m upfront for cyclin-dependent kinase 9 (CDK9) rights.
Reaches final event trigger on 28 Oct 2026 across 126 CR2 patients.
Reports 24.0-month median OS; stock jumps +156%; launches $150m deal after close.
Source: FY2025 Form 10-K; 2026 DEF 14A proxy; 17 Nov 2026 releases (intellectual property, IP). Blue cells mark strategic pivots.
Source: SEC filings; Penmark Research model (FY26E current burn vs FY35E scale economics).
| Partner (date) | Scope | Milestones & fees | Royalties & model treatment |
|---|---|---|---|
| MSK (Sep 2014) | Global WT1 vaccine (GPS) in-licence | $0.1m/yr minimum; up to $17.4m/product + $2.8m patent | Mid-single-digit tiered; modelled at 5.0% global sales + $17.4m milestones. |
| GenFleet (Mar 2022) | Ex-Greater China CDK9 (SLS009) | $10.0m paid; up to $48.0m dev/reg + $92.0m sales | Single-digit tiered; modelled at 6.0% sales + $15.0m approval milestone. |
| 3D Med (Dec 2020) | Greater China GPS out-licence | $191.5m remaining; arbitration dismissed Jul 2026 ($1m fee) | High-single to low-double-digit royalty; valued at $0m pending China trials. |
Source: FY2025 Form 10-K; Q3 2026 Form 10-Q; Penmark Research model.
Variable manufacturing is asset-light, but commercial build is fixed. Contract manufacturers supply GPS peptides, Montanide adjuvant and GM-CSF (~10% COGS) while GenFleet supplies small-molecule SLS009 (~5% COGS), requiring zero plant capex. Conversely, hiring ~60 US oncology reps creates $45m–$60m of fixed annual field expense regardless of uptake.
Working capital absorbs 15% of incremental US sales. Specialty distributor receivables and launch vials consume $39.6m of unrisked cash across FY28E–FY30E before releasing cash after FY40E exclusivity ends.
GPS accounts for 93% of gross programme rNPV before $518.2m of overhead and tax
High mature margins arrive late: After NOLs exhaust in FY33E, 24% cash tax ($94.2m) leaves $290.3m (51.5%) of unlevered programme FCF, or $319.0m company FCF including $28.7m treasury interest.
Source: Penmark Research model (FY2035E probability-weighted flows).
Stage gap outside CR2: GPS CR1 rests on Phase 2 data (n=22), while SLS009 frontline Phase 2 is half-enrolled (40 of 80 patients per the 4 Nov 2026 release).
Source: SEC filings; 4 Nov and 17 Nov 2026 company releases; Penmark Research model.
Programme value bridge: GPS CR2 ($3.03/sh) and GPS CR1 ($2.49/sh) drive enterprise value; net cash, offering and future raises add $1.31/sh to reach $4.97/sh.
Source: Penmark Research model (present values at 17 Nov 2026, 11.1% cost of equity).
Unfit second remission offers 1,701 US patients yearly against 7,718 in first remission
Acute myeloid leukaemia (AML) is an aggressive blood cancer of older adults, where non-transplant maintenance pools are 4.5 times larger in first remission than in second remission. Bottom-up epidemiology caps unrisked US second-remission sales at $418.5m by FY40E, forcing bulls to lean on unstarted earlier-line trials.
Source: SELLAS Feb 2026 deck; Penmark Research model (parallel non-transplant CR1 pool = 70% of 11,025 = 7,718 patients).
Source: Penmark Research model (FY2040E GPS, FY2041E SLS009 peak revenue to SELLAS).
Source: FY2025 Form 10-K; Q3 2026 Form 10-Q; Penmark Research model (clinical research organisations, CROs; European Medicines Agency, EMA).
Bottom-up market size and patient pools
Adult AML incidence grows slowly (~1% a year) while remission attrition narrows the addressable market. Management estimates roughly 21,000 US adults develop AML annually (within the American Cancer Society’s 22,010 total US cases in 2025), alongside ~16,000 in the EU5 and ~4,500 in Japan. Only 12%–15% (13.5% midpoint, or 2,835 US patients) achieve second complete remission (CR2), and 60% are ineligible for stem-cell transplant due to age (median 73–74 in Phase 2) or frailty, leaving 1,701 eligible patients.
Earlier-line pools are 4.5 times larger but clinically contested. About 52.5% of incident AML patients reach first complete remission (CR1) and 70% (7,718 patients, or 4.5x the 1,701 CR2 pool) do not undergo transplant. Separately, poor-prognosis genetic subsets (ASXL1 ~20%, TP53 and monocytic disease) represent ~30% (6,300 US patients) for tambiciclib (SLS009).
Pricing, profit pool and substitution
Orphan blood-cancer pricing supports ~60% mature contribution margins in the US. Relapsed AML benchmarks carry high wholesale acquisition costs (WAC): Syndax’s Revuforj launched at $39,500 a month ($474k annualised list price before statutory and payer rebates). Because GPS tapers to one booster every six weeks after week 52, we model $300k US net revenue per patient-year (+2%/yr net inflation) and $250k for add-on SLS009.
Contract manufacturing and upstream royalties claim 11%–15% of US sales. Sole-source contract manufacturers (Polypeptide Group for peptides and LSNE/PCI for drug product) and licensor royalties (5% MSK, 6% GenFleet) take 11%–15% of US net revenue. Ex-US markets price near 45% of US levels, yielding a 20% partner royalty to SELLAS after a two-year regulatory lag, while menin inhibitors and venetoclax triplets threaten to reshape downstream CR2 relapse pools.
REGAL gives GPS a 9.3-month survival lead in CR2, while CR1 faces oral incumbents
GPS holds the only positive randomised overall-survival (OS) readout in transplant-ineligible CR2 maintenance, supporting 45% peak share in our base case. Outside CR2, oral azacitidine (Onureg) and launched targeted inhibitors hold entrenched labels, commercial scale and oral convenience.
Source: FDA product labels; 17 Nov 2026 REGAL release; Penmark Research assessment.
Source: 17 Nov 2026 REGAL release; 4 Nov 2026 ASH release; Feb 2026 deck (relapse-free survival, RFS; SLS009 vs ~2.5-month historical benchmark).
Clinical caveats matter: GPS remains investigational pending full REGAL curves and FDA review, while SLS009’s 8.8-month TP53 survival is an unrandomised historical comparison.
| Therapy (owner) | AML setting & status | Clinical benchmark | Route & schedule | Competitive implication for SELLAS |
|---|---|---|---|---|
| GPS vaccine (SELLAS) | Investigational; CR2 maintenance (BLA H1 27); CR1 Ph2 | REGAL CR2 OS 24.0 months vs 14.7 months (HR 0.59, p=0.035); CR1 Ph2 n=22 | Subcutaneous + GM-CSF; tapers to q6w after wk 52 | First randomised CR2 OS proof; CR1 requires 5-yr Ph3 vs Onureg. |
| SLS009 / tambiciclib (SELLAS) | Investigational; Ph2 r/r & frontline AML + Aza/Ven | 34% all-dose r/r ORR; 54% monocytic, 57% TP53 at 30 mg BIW | Twice-weekly (BIW) IV infusion (30 mg) | Promising venetoclax-resistant activity, but clinic IV add-on; 13% base odds. |
| Onureg (Bristol Myers Squibb) | FDA approved: CR1 maintenance post-intensive chemo | Established Phase 3 OS standard in adult CR1 maintenance | Oral tablet, 14 days per 28-day cycle | Incumbent oral CR1 standard; caps GPS CR1 base share at 20%. |
| Revuforj & Komzifti (SNDX / KURA) | FDA approved: relapsed/refractory menin-driven AML | Approved oral menin inhibitors ($333m Syndax total [Revuforj & Niktimvo]; $91m Kura) | Oral daily ($474k Revuforj annual WAC) | Deepening frontline/relapsed remissions could shrink unfit CR2 relapse pool. |
| Rezlidhia & Vanflyta (RIGL / Daiichi) | FDA approved: mIDH1 r/r AML & FLT3-ITD AML | Biomarker-defined targeted standards (RIGL $324m run-rate sales) | Oral daily targeted maintenance / salvage | Fragment molecular AML subsets where targeted pills take precedence. |
| HMA + venetoclax / observation | Standard off-label CR2 control arm in REGAL | 14.7-month median OS in REGAL control; myelosuppression in elderly | Cyclic IV/SC HMA + daily oral venetoclax | Cytopenia burden in frail CR2 patients favours well-tolerated vaccine. |
Source: SEC filings; REGAL/ASH releases; Penmark Research model (hazard ratio, HR; overall response rate, ORR; twice weekly, BIW; intravenous/subcutaneous, IV/SC).
Customer choice criteria and vaccine moat
Tolerability in frail septuagenarians reinforces GPS’s survival edge in CR2. Haematologists treating older remission patients weigh survival extension against bone-marrow suppression. Across Phase 2 AML and myeloma cohorts, GPS caused mainly mild-to-moderate local skin reactions and fatigue with no significant serious or high-grade systemic adverse reactions attributable to GPS, contrasting sharply with chronic hypomethylating agent (HMA) plus venetoclax cytopenias.
Intellectual property vs biologic exclusivity
Regulatory exclusivity, not composition patents, underpins 2036–2040 cash flows. US composition-of-matter patents covering GPS’s four WT1 peptides expire in 2034–2035 (next-generation heptavalent GPS+ filings run to 2040). Our FY2040E cliff therefore relies on 12-year US biologic reference-product exclusivity from FY2028E BLA approval, whereas commercial rivals already field oncology sales teams against SELLAS’s 13-employee roster.
Insiders hold 1.3%; share count rose from 15.5m (FY21A) to 212.4m (FY26E)
| Who | Tenure & prior role | How they are paid (FY2025) | What they own (at $19.15/sh) |
|---|---|---|---|
| Angelos M. Stergiou, M.D. President, CEO & Director Founder (2012) |
8.9 yrs public CEO (Dec 2017); 14.0 yrs incl. Private SELLAS. Prior: Genesis Life Sciences (COO), Biovest (CMO). | $1.88m: 36% salary/other ($0.68m), 21% bonus ($0.39m), 43% equity ($0.80m). 100% corporate clinical/cash goals (weights n.d.). |
$21.70m (1.13m sh; 0.56% of 203.53m sh; 32.1x salary). Form 4: 1.07m restricted stock unit (RSU) grant Jun 2026 (1.76m sh after); no 2026 open-market Form 4 trades. |
| John T. Burns, CPA SVP & Chief Financial Officer |
3.8 yrs in role (Feb 2023); 13.5 yrs at SELLAS (May 2013). Prior: Pixelworks (SEC Reporting Mgr), Moss Adams. | $0.96m: 46% salary/other ($0.45m), 19% bonus ($0.19m), 34% equity ($0.33m). Corporate & individual goals (weights n.d.). |
$6.97m (0.36m sh; 0.18% of shares; 16.2x salary). Form 4: equity awards only in 2026; no open-market buys or sales. |
| Dragan Cicic, M.D. SVP & Chief Development Officer |
2.9 yrs in role (Jan 2024); 6.8 yrs at SELLAS (Feb 2020). Prior: Klus Pharma (SVP Clinical), Actinium Pharma. | $0.99m: 47% salary/other ($0.47m), 19% bonus ($0.19m), 33% equity ($0.33m). Corporate clinical & individual goals (weights n.d.). |
$7.68m (0.40m sh; 0.20% of shares; 17.0x salary). Form 4: equity awards only in 2026; no open-market buys or sales. |
| John Varian Independent Chair of the Board |
2.4 yrs as Chair (Jun 2024); 8.9 yrs on Board (Dec 2017). Prior: XOMA Corp. (CEO), ARYx Therapeutics (COO). | $0.12m: 78% cash fees ($0.09m), 0% bonus, 22% annual equity ($0.03m). Fixed retainer plus time-vested director grants. |
$1.59m (0.08m sh; 0.04% of shares; 16.9x cash fees). Form 4: annual board grants in 2026; no open-market trades. |
Source: April 2026 DEF 14A proxy (FY2025 pay; beneficial holdings as of 15 Apr 2026 include common shares and options exercisable within 60 days, excluding unvested awards; % vs 203.53m Q3 2026 shares) and SEC Form 4 filings to Nov 2026; zero new executives in last 12 months.
Source: FY2025 Form 10-K and Q3 2026 Form 10-Q cash flow statements.
Source: SEC Form 10-K filings (FY21A–FY25A weighted); Penmark Research model (FY26E–FY29E year-end).
Pay design, governance and plan dilution
Executive pay rewards clinical execution rather than per-share value. Short-term cash bonuses track annual trial and funding goals without per-share return hurdles, while option and restricted stock unit (RSU) grants vest purely on time. At the June 2026 annual meeting, stockholders expanded the 2023 Equity Plan by 20.0m shares (~9.8% of Q3 shares), unlocking CEO Stergiou’s 1.07m RSU grant.
Board structure is independent and non-controlled. Five of six directors are independent under John Varian’s separate chair, hedging and pledging are barred, a clawback policy applies, and all eight insiders hold 2.42m shares (1.3% of April 2026 shares) with one-share-one-vote common stock.
Capital allocation and what it means for value
Opportunistic equity raises preserved clinical survival at heavy per-share cost. Management kept annual operating cash burn to $28.4m–$35.4m in FY24A–FY25A using 13 staff, raising $218.3m across FY24A–9M26 (including $85.3m of 9M26 financing inflows from warrant exercises) before proposing a $150m offering after the 17 Nov close.
Issuing shares at $17.00 lifts our cash floor to $1.19 per share. Raising capital well above intrinsic value cushions downside, yet spreading GPS across 230.85m fully diluted shares caps base rNPV at $4.97 per share.
Binary REGAL readouts explain 70% of return shocks while dilution absorbs 5-year gains
SELLAS trades on clinical survival readouts, implied peak-sales multiples and share-supply events rather than quarterly earnings. SELLAS holds no quarterly earnings calls, so we evaluate stock drivers across event-day reactions, multi-year return decomposition and daily factor regressions.
| Stock driver | What moves the stock | Empirical basis | Market move vs model value | Linked debate | Next number to watch |
|---|---|---|---|---|---|
| REGAL survival & FDA odds | Event-count updates, topline HR 0.59 readout (+156.4%) and FDA single-trial filing stance. | Event days, 5Y returns & daily R² (30.7%) | +$11.68/sh (+156%) on 17 Nov vs +$1.39/sh for 100% CR2 odds ($10.29/sh excess). | Single-trial approval | Full REGAL prior-venetoclax & cytogenetic subgroups (Dec 26–H1 27). |
| GPS peak-sales expectations | Re-rating of EV / FY30E risk-adjusted revenue from 0.9x to 21.8x on orphan pricing hopes. | 5Y return split & EV/sales expansion | $19.15 implies $4,923m US peak vs $6.57–$6.92/sh at 65% share or $400k price. | Orphan net pricing & unfit CR2 uptake | ASH haematologist & payer feedback (Dec 2026; $300k base vs $400k market). |
| Equity dilution & share supply | Follow-on offerings, warrant inducements and 20m-share equity plan expansion. | After-hours deal move & 5Y cap/price gap | 5Y market cap +3,346% vs price +171%; shares traded 12% lower after hours on the $150m deal ($16.61–$16.90). | CR1 maintenance expansion | Final $150m offering price & shares (Nov 2026; Penmark $17.00/sh, 8.82m sh). |
Source: Yahoo Finance daily returns to 17 Nov 2026; SEC Form 8-K, Form 10-K and Form 10-Q filings; Penmark Research model (SELLAS holds no quarterly earnings calls).
Source: Yahoo Finance event-day closes; SEC Form 8-K filings and press releases.
Source: Yahoo Finance; SEC filings (17 Nov 2021 to 17 Nov 2026; 3Y SLS +1,834% vs XBI +100%).
Model value share vs market move or price
Blue = Penmark Research model value share; grey = unbacked excess in 17 Nov price.
Return decomposition shows multiple expansion, not revenue, drove trailing returns. Over 1, 3 and 5 years to 17 Nov 2026, SLS returned +1,258%, +1,834% and +171% with zero product revenue or dividends, vs +26.5%, +99.9% and +18.2% for the SPDR S&P Biotech ETF (XBI).
Daily variance rests on binary GPS readouts while quarterly filings fail to move SLS
Source: Yahoo Finance daily returns (N=251 to 17 Nov 2026); Penmark ordinary least squares (OLS) dummy R².
| Candidate factor | Evidence across 251 daily observations | Share | Why secondary |
|---|---|---|---|
| Quarterly GAAP EPS & burn | Pure 10-Q days moved −4.6% (Q3 26) and +0.1% (Q2 26) on filing dates. | 0.13% SS | Market looks past pre-revenue losses when cash covers trial readouts. |
| SLS009 Phase 2 updates | Standalone SLS009 days moved −8.2% to +4.6% across study updates. | 0.27% SS | Early stage ($0.39/sh rNPV) makes SLS009 secondary to GPS. |
| 10Y US Treasury yield | Daily yield changes show non-significant sensitivity (slope −0.29, p=0.096). | 1.11% R² | Idiosyncratic clinical swings swamp discount-rate sensitivity. |
| Biotech ETF (XBI) & S&P 500 | XBI explains 6.35% of daily variance (p<0.001); S&P 500 explains 1.09% (p=0.099). | 6.35% R² | Sets background beta between catalysts rather than re-rating SLS. |
Source: Yahoo Finance daily closes (18 Nov 2025 to 17 Nov 2026); SEC filing dates; Penmark Research regressions (sum of squares, SS).
REGAL survival & FDA odds: market prices more than 100% single-trial certainty
Links to single-trial approvalMarket reaction vs model value: REGAL event days generated 69.8% of raw 1-year squared daily returns (30.7% OLS dummy R²), culminating in a +$11.68/sh (+156.4%) jump on 17 Nov 2026 (~$2.38bn cap added). Lifting GPS CR2 approval probability from our 65% base to 100% adds just +$1.39/sh (from $4.97 to $6.36/sh), leaving a $10.29/sh (88%) excess move.
Next number to watch: Full REGAL subgroup splits (prior venetoclax and cytogenetics), censoring/salvage-therapy details and secondary endpoints (Dec 26–H1 27), followed by H1 27 FDA pre-BLA minutes. With HR 0.59 and p=0.035 across 80 deaths, the undisclosed 95% CI upper bound sits about 0.90–0.96, leaving subgroup consistency critical to first-cycle approval.
GPS peak-sales expectations: price implies 3.44x our modelled CR2 plus CR1 US peak
Links to orphan net pricing & unfit CR2 uptakeMarket reaction vs model value: Over 12 months, EV / FY30E risk-adjusted revenue expanded from 0.87x to 21.77x vs 2.35x for commercial oncology peers. At $19.15, reverse-rNPV implies $4,923m of US peak GPS sales vs $1,431m modelled; conceding $400k net pricing ($6.92/sh) or 65% CR2 share ($6.57/sh) still leaves a $12.23–$12.58/sh (64%–66%) valuation gap.
Next number to watch: Haematologist and payer pricing feedback around the December 2026 ASH meeting and H1 2028 US launch WAC. Penmark models $300k/yr net on 6-week maintenance dosing vs the $400k/yr market view, a $1.95/sh full-model difference.
Equity dilution & share supply: recurring share issuance caps per-share compounding
Links to CR1 maintenance expansionMarket reaction vs model value: Five-year market value rose +3,346% while share price rose +171% as common shares grew 12.7 times; after the 17 Nov close ($19.15, below the $24.89 regular-session peak), launching a proposed $150m offering sent after-hours trade down 12% ($16.61–$16.90). Issuing 8.82m assumed shares at $17.00 ($140.25m net) plus 5.74m FY28E–FY29E shares lifts diluted shares to 230.85m while raising the cash floor to $1.19/sh.
Next number to watch: Final pricing and share count of the $150m underwritten offering (Nov 2026; $22.5m option excluded until exercised). Pricing below our assumed $17.00/sh increases share issuance above 8.82m shares.
Even 100% CR2 approval values SLS at $6.36 because only 1,701 US adults qualify
Source: Penmark Research model.
What the market believes
At $19.15, investors extrapolate positive CR2 survival into multi-billion-dollar franchise sales. The $19.15 share price ($3,763m enterprise value) implies a 3.44x market-sizing scalar on GPS ($4,923m peak US net sales across CR2 and CR1 vs $1,431m modelled), while $35–$40 sell-side targets demand even more.
| Commercial parameter | Penmark | Market 1-lever | 100% CR2 | Price-implied |
|---|---|---|---|---|
| US adult AML incidence (2026) | 21,000 | 21,000 | 21,000 | 21,000 |
| CR2 unfit US pool (13.5% × 60%) | 1,701 | 1,701 | 1,701 | 5,851 eq. |
| CR2 peak penetration | 45.0% | 65.0% | 45.0% | 3.44x scalar |
| Mean treatment duration (yrs) | 1.25 | 1.25 | 1.25 | 1.25+ |
| US net price / patient-yr ($k) | $300k | $400k | $300k | $300k+ |
| CR2 peak US net sales, unrisked | $418.5m | $557.9m–$604.4m | $418.5m | $1,439.5m |
| CR2 + CR1 peak US net sales | $1,431.0m | $1,617m–$1,908m | $1,431.0m | $4,922.7m |
| Implied SLS value / share | $4.97 | $6.57–$6.92 | $6.36 | $19.15 |
Source: SELLAS Feb 2026 corporate presentation; Penmark Research model.
Three independent sources of evidence
1. Company & ACS epidemiology fix the unfit CR2 ceiling near 1,700 patients. SELLAS guides to 21,000 US adult AML cases annually (aligned with 22,010 total US cases estimated by the American Cancer Society), with 12%–15% reaching CR2 and ~60% ineligible for transplant: 1,701 patients before biomarker or frailty exclusions.
2. Maintenance dosing cadence constrains annual net pricing. Syndax’s oral menin inhibitor Revuforj carries a $474k annual wholesale acquisition cost ($39,500/month) before gross-to-net rebates for daily relapse therapy. GPS tapers to one subcutaneous booster every six weeks after week 52 (~8–9 doses/year in year two), anchoring our $300k/yr net assumption across 1.25 patient-years.
3. Launched AML peers generate $91m–$333m today, not $4.9bn. Commercial peers Syndax ($333m total annualised Q3 sales across Revuforj and Niktimvo), Rigel ($324m) and Kura ($91m) trade at 1.9x–2.4x sales, confirming niche AML commercial ceilings.
What it is worth & strongest counter-evidence
GPS CR2 contributes $698.8m ($3.03/sh) of risk-adjusted NPV. Even unrisked at 100% approval, CR2 NPV is $1,167.6m ($5.06/sh before overhead and tax), lifting total equity value by +$1.39/sh to $6.36/sh. Raising net pricing to the market’s $400k/yr view adds +$1.95/sh ($6.92/sh), and 65% CR2 uptake adds +$1.60/sh ($6.57/sh).
Counter-evidence: In our bull case (20% weight), if 70% of CR2 patients are transplant-ineligible, 70% adopt GPS for 1.75 years (21 months of maintenance) at $450k/yr net and CR1 approval odds rise to 50%, equity value reaches $26.77/sh, still 24%–33% below $35–$40 Street targets.
One open-label 126-patient study leaves a 35% risk of FDA delay or rejection
Source: BIO/Informa/QLS 2011–2020 all-indication base rates; Penmark Research model.
What the market believes
Consensus models commercial sales in FY2027E before FDA review typically concludes. Simply Wall St’s single revenue estimate projects $53m in FY27E and $122m in FY28E, while traders treat the 17 Nov headline (HR 0.59, p=0.035) as de-risking Biologics License Application (BLA) approval above 85%.
| FDA review item | Disclosed on 17 Nov 2026 | Undisclosed / review risk |
|---|---|---|
| Trial design & size | 126 CR2 patients, 1:1 open-label vs best available therapy. | Single open-label trial; post-relapse salvage crossover unblinded. |
| Statistical strength | 80 deaths; HR 0.59; two-sided p=0.035; 24.0-month vs 14.7-month OS. | 95% CI undisclosed; p=0.035 gives less cushion than p<0.01 single-trial benchmarks. |
| Protocol changes | Final trigger revised from 105 to 80 deaths in Nov 2022. | FDA scrutiny of sample-size/event revisions and interim alpha spend. |
| Subgroup & secondary | Topline primary OS met; safety consistent with prior trials. | Leukemia-free survival, MRD and prior-venetoclax splits pending. |
| Biologic CMC | Peptide synthesis (Polypeptide) & lyophilisation (LSNE/PCI). | Four-peptide potency assays and commercial lot inspection required for BLA. |
Source: FY2025 Form 10-K; 17 Nov 2026 REGAL topline release; Penmark Research model (measurable residual disease, MRD).
Three independent sources of evidence
1. REGAL’s 17 Nov press release omits confidence bounds and secondary endpoints. While a 0.59 hazard ratio across 80 deaths is clinically meaningful, two-sided p=0.035 implies an upper 95% confidence bound about 0.90–0.96 under proportional-hazards math, leaving limited cushion if censoring or salvage imbalances emerge.
2. Single-pivotal review weighs both statistical strength and open-label design. Industry-wide BLA-to-approval success is 90.6% across all-indication filings (BIO 2011–2020 base rate); for a single 126-patient open-label oncology study where target deaths were lowered from 105 to 80 in 2022, FDA could request a pre- or post-approval confirmatory study.
3. Biologic filing timelines make FY2027E product sales unlikely; we assume H1 2028 approval. Management guides to BLA submission in H1 27 after pre-BLA discussions; even under Priority Review, a Prescription Drug User Fee Act (PDUFA) decision would likely fall in late 2027 or H1 2028, making $53m of FY27E consensus revenue unlikely.
What it is worth & strongest counter-evidence
Regulatory outcomes swing value from $0.18 in our bear case to $5.77 at 85% odds. In our sensitivity grid, lowering CR2 approval odds from 65% to 45% at $300k pricing cuts value to $4.18/sh; combining 40% CR2 odds, a confirmatory-trial delay to FY29E, $200k pricing and lower uptake yields our $0.18/sh bear case (30% weight). Conversely, 85% odds lift base value by +$0.79/sh to $5.77/sh.
Counter-evidence: Overall survival is an objective endpoint, GPS holds FDA Orphan Drug and Fast Track designations in AML, and unfit CR2 patients lack an FDA-approved remission maintenance therapy; accordingly, we model 65% approval (more likely than not) with a post-marketing commitment in our base case.
BLA filing, pre-launch build and a five-year CR1 trial lift FY27E spend to $110.2m
Source: Penmark Research model (risk-adjusted operating & COGS spend, FY27E–FY32E).
| Programme / block | Odds | Launch | Pre-approval / fixed spend | rNPV ($m) | $/sh |
|---|---|---|---|---|---|
| GPS AML CR2 (REGAL) | 65.0% | FY28E | $65.2m over FY27E–FY28E ($60.1m PV) | $698.8m | $3.03 |
| GPS AML CR1 expansion | 30.0% | FY32E | $95m 5-yr Ph3 (FY27E–FY31E) | $574.4m | $2.49 |
| SLS009 / tambiciclib | 13.0% | FY31E | $15m Ph2 + $105m 3-yr Ph3 (FY28E+) | $89.7m | $0.39 |
| Corporate G&A / R&D PV | 100% | n.a. | $25m+ / yr (+4%/yr G&A) | −$235.2m | −$1.02 |
| Cash tax after $77.7m NOLs | Prob. | FY30E | 24% effective tax rate | −$283.1m | −$1.23 |
| Net cash, offering & future raises | n.a. | n.a. | +5.7m sh raised FY28E–FY29E | $303.5m | $1.31 |
| Base-case equity rNPV | n.a. | n.a. | 230.85m diluted shares | $1,148.2m | $4.97 |
Source: Penmark Research model.
What the market believes & three sources of evidence
Consensus models a $26m net loss in FY27E narrowing close to breakeven (−$4m) in FY28E while awarding pipeline upside. Three primary sources contradict that path:
1. CR1 rests on a 22-patient single-arm Phase 2 study against an oral incumbent. BMS’s oral Onureg already owns FDA-approved CR1 maintenance; proving OS superiority or add-on benefit requires a five-year, $95m randomised Phase 3 trial starting FY27E for FY32E launch (30% odds).
2. SLS009 remains mid-Phase 2 with GenFleet milestone obligations. Only 40 of 80 patients were enrolled in frontline Phase 2 per the 4 Nov 2026 release, twice-weekly (BIW) IV dosing adds clinic visits, and GenFleet is owed up to $48m in development/regulatory and $92m in sales milestones plus single-digit royalties.
3. BLA filing, pre-launch preparation and CR1 Phase 3 lift FY27E spend to $110.2m. FY27E spend spans BLA/CMC and the MSK filing milestone ($35.2m), pre-launch commercial preparation ($20.0m), trials ($30.0m: CR1 Phase 3 year 1 plus SLS009 Phase 2 completion) and corporate overhead ($25.0m); the ~60-rep US field force ($45m launch year; $60m at scale) and SLS009 Phase 3 ($35m/yr) begin in FY28E.
What it is worth & strongest counter-evidence
CR1 ($2.49/sh) and SLS009 ($0.39/sh) add $2.88/sh, largely offset by −$2.24/sh of corporate overhead and taxes. Even after assuming $140.25m net proceeds from the 17 Nov offering ($262.1m end-FY26E cash), cumulative FY27E–FY29E free cash outflow of $223.8m triggers $36.7m of new equity (5.74m shares) in FY28E–FY29E to defend a $75m minimum cash buffer.
Counter-evidence: Lifting CR1 approval odds to 45% adds +$1.09/sh (to $6.06/sh), while unvalued 3D Medicines Greater China milestones total up to $191.5m ($0.83/sh unrisked before discounting) if Chinese development resumes after the July 2026 arbitration dismissal.
Zero product sales keep GAAP losses aligned with external trial cash burn
| US$m (except per share & shares) | FY21A | FY22A | FY23A | FY24A | FY25A | 9M26A |
|---|---|---|---|---|---|---|
| Licensing & milestone revenue (no product sales) | $7.60 | $1.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research & development (R&D) expense | −$15.67 | −$20.27 | −$24.01 | −$19.10 | −$16.02 | −$18.43 |
| General & administrative (G&A) expense | −$11.32 | −$12.58 | −$13.86 | −$12.42 | −$12.25 | −$12.76 |
| In-process R&D licence acquisition fees | −$5.70 | −$10.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating loss (GAAP) | −$25.29 | −$41.95 | −$37.87 | −$31.51 | −$28.27 | −$31.19 |
| Interest & other income, net | $4.36 | $0.65 | $0.53 | $0.63 | $1.41 | $3.09 |
| GAAP net loss (no non-GAAP adjustments reported) | −$20.70 | −$41.30 | −$37.34 | −$30.88 | −$26.86 | −$28.10 |
| Stock-based compensation (SBC, inside opex) | $1.01 | $1.73 | $2.09 | $1.56 | $1.96 | $3.75 |
| Operating cash flow (OCF / free cash flow) | −$26.02 | −$23.81 | −$31.41 | −$35.40 | −$28.39 | −$22.37 |
| OCF less GAAP net loss (working capital & SBC gap) | −$5.32 | +$17.49 | +$5.93 | −$4.52 | −$1.53 | +$5.73 |
| Reported diluted EPS ($/sh) / weighted shares (m) | −$1.34 / 15.5 | −$2.13 / 19.4 | −$1.34 / 27.8 | −$0.50 / 61.2 | −$0.25 / 109.1 | −$0.15 / 188.0 |
| Period-end cash & equivalents ($m; zero debt) | $21.36 | $17.13 | $2.53 | $13.89 | $71.79 | $134.71 |
Source: SEC Form 10-K (FY21A–FY25A, incl. $0.20m/$0.10m FY21A/22A licence cost of revenue and $0.24m FY21A tax benefit) and Q3 2026 Form 10-Q.
Source: SEC Form 10-K and Form 10-Q filings (1Q24–3Q26).
Source: SEC Q3 2026 Form 10-Q ($0.24m R&D SBC inside Personnel & SBC).
Accounting quality and cash conversion
Reported GAAP numbers are clean, with all R&D expensed as incurred and no non-GAAP adjustments reported. Clinical, manufacturing and GenFleet/MSK licence outlays flow directly through operating expense. Narrowing per-share losses from −$2.13 in FY22A to −$0.25 in FY25A came from weighted shares expanding 5.6x rather than lower burn.
Stock-based compensation rose 2.5x year on year in 9M26. SBC reached $3.75m in 9M26 (vs $1.51m in 9M25; $1.93m in 3Q26 alone) after the June 2026 plan expansion; our model keeps SBC inside operating costs as a real expense.
Warrants, leases and Section 382 tax shields
Equity-classified warrants avoid P&L mark-to-market noise while adding real share overhang. Net warrant and financing inflows totalled $85.3m during 9M26, leaving 8.12m warrants at a $2.07 average strike (7.24m treasury-method shares at $19.15).
Tax shields carry unmodelled Section 382 risk. Federal net operating loss (NOL) carryforwards stood at $77.7m at Dec 2025 (capped at 80% of post-2017 taxable income), and repeated 2023–2026 equity raises could limit annual utilisation.
Risk-adjusted revenue starts at $19.0m in FY28E and reaches $563.3m in FY35E
We model explicit programme cash flows from Q4 2026 through FY2045E using the pipeline driver tree shown in the business chapter. Each indication multiplies US eligible AML patients (+1%/yr demographic growth) by a four-year orphan uptake ramp (20%, 55%, 85%, 100%), peak share, treatment duration and net price (+2%/yr), plus a 20% royalty on lagged ex-US partner sales.
| Programme driver / revenue ($m) | FY26E | FY27E | FY28E | FY29E | FY30E | FY32E | FY35E | FY40E |
|---|---|---|---|---|---|---|---|---|
| GPS AML CR2 maintenance (65% base approval odds; FY28E H1 US launch) | ||||||||
| US eligible unfit CR2 patients (#) | 1,701 | 1,718 | 1,735 | 1,753 | 1,770 | 1,806 | 1,860 | 1,955 |
| Treated US patient-years (45% peak × 1.25y) | 0 | 0 | 98 | 542 | 846 | 1,016 | 1,046 | 1,100 |
| US net price / patient-yr ($k, +2%/yr) | n.a. | n.a. | $300.0 | $306.0 | $312.1 | $324.7 | $344.6 | $380.5 |
| GPS CR2 revenue, approval case (incl. ex-US) | $0.0 | $0.0 | $29.3 | $165.9 | $265.9 | $345.7 | $381.0 | $442.1 |
| GPS CR2 risk-adjusted revenue (65%) | $0.0 | $0.0 | $19.0 | $107.8 | $172.8 | $224.7 | $247.7 | $287.4 |
| Follow-on programmes (GPS CR1 at 30% odds, FY32E launch; SLS009 at 13% odds, FY31E launch) | ||||||||
| GPS CR1 risk-adjusted revenue (20% peak share) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $23.9 | $269.9 | $320.9 |
| SLS009 risk-adjusted revenue ($250k base price) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $21.9 | $45.7 | $53.5 |
| Total company risk-adjusted revenue ($m) | $0.0 | $0.0 | $19.0 | $107.8 | $172.8 | $270.6 | $563.3 | $661.8 |
Source: Penmark Research model (ex-US royalties launch two years after US at 20% of partner net sales; CR1/CR2 pool overlap not modelled).
Source: Company filings (FY24A–FY25A); Penmark Research model (FY26E–FY35E).
Launch cadence and ex-US royalty lag
H1 27 BLA filing puts first US CR2 revenue in FY28E ($29.3m approval case; $19.0m risk-adjusted). Assuming mid-year launch (0.5x year-one sales fraction) and four-year orphan haematology adoption, CR2 reaches full penetration in FY31E ($330.1m approval case). Ex-US sales equal 30% of US sales on a two-year lag, yielding 20% partner royalties (~5% of revenue; $191.5m 3D Medicines milestones unvalued).
Exclusivity horizon and zero terminal value
Risk-adjusted revenue peaks at $661.8m in FY40E before biosimilar erosion. We model 12-year US biologic exclusivity for GPS through FY40E (though composition patents expire in 2034–2035) and SLS009 exclusivity through FY41E, followed by 50% annual erosion through FY45E (4.5% of peak sales) with zero terminal value.
Pre-launch build lifts FY27E net loss to $101.0m vs $26.0m in stale consensus
| US$m (probability-weighted) | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY32E |
|---|---|---|---|---|---|---|---|
| Risk-adjusted revenue | $0.0 | $0.0 | $0.0 | $19.0 | $107.8 | $172.8 | $270.6 |
| Variable COGS & MSK/GenFleet royalties (11%–15%) | $0.0 | $0.0 | $0.0 | −$2.9 | −$16.2 | −$26.0 | −$40.7 |
| Semi-fixed trial R&D, BLA & US field force | −$16.0 | −$27.4 | −$85.2 | −$87.6 | −$82.8 | −$81.9 | −$50.0 |
| Fixed corporate G&A & platform overhead (+4%/yr G&A) | −$12.3 | −$17.8 | −$25.0 | −$25.8 | −$26.6 | −$27.5 | −$29.3 |
| Risk-adjusted EBITDA (turns positive FY30E) | −$28.3 | −$45.2 | −$110.2 | −$97.2 | −$17.7 | $37.4 | $150.5 |
| Treasury interest (3.5%) less cash tax (24% post-NOL) | $1.4 | $4.3 | $9.2 | $5.6 | $2.6 | $0.8 | −$0.5 |
| Net income ($m) | −$26.9 | −$40.9 | −$101.0 | −$91.5 | −$15.1 | $38.2 | $150.0 |
| Working capital / non-cash adj. (15% of ΔUS rev.) | −$1.5 | $5.7 | $0.0 | −$2.9 | −$13.3 | −$9.6 | −$7.2 |
| Free cash flow (incl. interest; zero capex) | −$28.4 | −$35.2 | −$101.0 | −$94.4 | −$28.4 | $28.6 | $142.7 |
| Net equity raised ($140.3m 4Q26E deal; FY28E–29E top-up) | $86.3 | $140.3* | $0.0 | $8.3 | $28.4 | $0.0 | $0.0 |
| Closing cash ($75.0m minimum liquidity policy) | $71.8 | $262.1 | $161.1 | $75.0 | $75.0 | $103.6 | $334.5 |
*FY26E cash roll also includes $85.3m of 9M26A warrant/financing inflows ($71.8m − $35.2m + $85.3m + $140.3m = $262.1m; 31.1-mo runway). Source: Penmark Research model.
| Metric & period | Cons. / Guide | Penmark | Reason for gap |
|---|---|---|---|
| FY26E revenue / EPS | $0m / −$0.28 | $0m / −$0.19 | Higher year-end share count (212.4m) dilutes loss per share. |
| FY27E revenue | $53.0m cons. | $0.0m | BLA files H1 27; FY27E sales unlikely (assume H1 28 approval). |
| FY28E revenue (unrisked) | $122.0m cons. | $29.3m ($19.0m r) | H1 28 launch (0.5x yr) & 20% yr-1 ramp on 1,735 pool. |
| FY27E / 28E net income | −$26m / −$4m | −$101m / −$92m | Appears not to include $55m BLA, $45m FY28E reps & Ph3 trials. |
| BLA & AML incidence | H1 27; 21k AML | 2027; 21k AML | Aligned with management operational guidance. |
| GPS exclusivity end | 2034–35 pat. | FY2040E | Models 12-yr US biologic exclusivity from FY28E BLA. |
Source: Simply Wall St / Seeking Alpha (1 estimate); company filings; Penmark Research model.
| Driver assumption shift | FY30E rev. | FY30E EPS | rNPV/sh |
|---|---|---|---|
| Base case (65% CR2, $300k) | $172.8m | $0.18 | $4.97 |
| CR2 odds 85% (single-trial approval) | $226.0m | $0.28 | $5.77 |
| CR2 odds 45% (FDA review risk) | $119.7m | $0.07 | $4.18 |
| US price $400k (orphan net pricing) | $230.5m | $0.36 | $6.92 |
| CR2 share 65% (unfit CR2 uptake) | $249.7m | $0.42 | $6.57 |
| CR1 odds 45% (CR1 maintenance) | $172.8m | $0.18 | $6.06 |
Source: Penmark Research model.
Operating leverage flips FCF positive in FY30E once CR2 scales. With 10% peptide COGS and a 5% MSK royalty (~85% contribution margin before field costs), company FCF (including treasury interest) reaches +$28.6m in FY30E and +$319.0m in FY35E ($290.3m unlevered).
Runway covers 31.1 months before two modest top-up raises. Starting from $134.7m Q3 cash plus $140.3m assumed net offering proceeds ($262.1m end-FY26E), SELLAS needs $8.3m in FY28E and $28.4m in FY29E (5.74m shares rolled at model value) to hold $75.0m minimum cash.
Sum-of-programmes rNPV values SELLAS at $4.97/sh base and $8.77/sh 12-month target
| Valuation component (17 Nov 2026 price date) | $m | $/sh |
|---|---|---|
| GPS AML CR2 maintenance (65% odds; $1,167.6m unrisked) | $698.78 | $3.03 |
| GPS AML CR1 expansion (30% odds; Ph3 FY27E–31E) | $574.43 | $2.49 |
| SLS009 / tambiciclib (13% odds; Ph2/Ph3 AML) | $89.71 | $0.39 |
| Corporate G&A and platform R&D present value | −$235.18 | −$1.02 |
| Cash taxes after $77.7m federal NOLs (24% rate) | −$283.06 | −$1.23 |
| Enterprise value (risk-adjusted NPV at 11.06% CoE) | $844.67 | $3.66 |
| Cash & equivalents (30 Sep 2026; $0.0m debt) | $134.71 | $0.58 |
| Assumed net proceeds of 17 Nov $150m offering ($17/sh) | $140.25 | $0.61 |
| Present value of FY28E–FY29E equity raises ($36.7m) | $28.56 | $0.12 |
| Base-case equity value (divided by 230.85m shares) | $1,148.19 | $4.97 |
| Diluted share & CoE build | Value |
|---|---|
| Common shares (30 Sep 2026) | 203.53m |
| Options (treasury @ $19.15; $3.21 strike) | 2.21m |
| Restricted stock units (RSUs) | 3.31m |
| Warrants (treasury @ $19.15; $2.07 strike) | 7.24m |
| Assumed 17 Nov offering shares ($17/sh) | 8.82m |
| Future FY28E–29E raise shares | 5.74m |
| Total diluted shares | 230.85m |
| Risk-free rate (10Y US Treasury, UST) | 5.12% |
| Beta (1.40x) × equity risk prem. (ERP 4.24%) | 5.94% |
| Cost of equity (= WACC; $0 debt) | 11.06% |
Source: Penmark Research model (cash floor = $1.19/sh from cash plus assumed offering divided by 230.85m shares).
Source: Penmark Research model (rounded to $0.01/sh).
Source: Penmark Research model; Maxim Group and Alliance Global Partners target prices.
Why programme rNPV fits a pre-revenue biotech
Near-term P/E and EV/EBITDA are meaningless while SELLAS posts clinical losses. Risk-adjusted net present value (rNPV) multiplies each drug’s approval-contingent cash flows by explicit clinical success odds while keeping committed pre-approval R&D unrisked at 100%.
Weighted average cost of capital (WACC) is the blended annual return required across debt and equity; with zero debt, WACC equals SELLAS’s 11.1% cost of equity. Beta (1.40x) blends 80% Damodaran US biotech beta (1.08x) and 20% SLS 5-year regression beta (2.70x) to avoid double-counting binary trial risk.
Finite drug life replaces perpetual terminal growth
Terminal growth is the perpetual annual rate at which a mature business grows after its forecast window; because drug patents expire, we set terminal value to zero. Explicit cash flows run to FY45E as biosimilars halve sales yearly after FY40E/41E exclusivity.
Future raises at model price are value-neutral per share. Issuing 5.74m FY28E–29E shares at rolled model value adds +$28.56m PV and +5.74m shares symmetrically, whereas the assumed $17.00/sh Nov 2026 deal is accretive to base value.
Peer exit cross-check yields $4.11/sh (−17.4% vs rNPV), confirming overvaluation
| Company (17 Nov 2026) | EV ($m) | Run-rate rev. | Rev. y/y | EV/sales |
|---|---|---|---|---|
| Syndax (SNDX · Revuforj & Niktimvo) | $642.7 | $333.2m | +81.6% | 1.93x |
| Kura (KURA · Komzifti) | $190.5 | $91.4m | +10.1% | 2.08x |
| Immunocore (IMCR · Kimmtrak) | $926.3 | $408.9m | −1.4% | 2.27x |
| Rigel (RIGL · Rezlidhia) | $787.5 | $323.6m | +16.5% | 2.43x |
| Geron (GERN · Rytelo)* | $732.1 | $240.8m | +27.4% | 3.04x |
| Iovance (IOVA · Amtagvi) | $3,061.3 | $485.9m | +80.1% | 6.30x |
| Peer median (6 launched peers) | $759.8 | $328.4m | +22.0% | 2.35x |
| SLS at actual $19.15 (vs FY30E rev.) | $3,762.8 | $172.8m | +60.3% | 21.77x |
| SLS at $8.77 target (vs FY30E rev.) | $1,749.3 | $172.8m | +60.3% | 10.12x |
*Geron EV overstated (marketable securities omitted in standardised data). Source: SEC Q3 2026 Form 10-Q filings; Yahoo Finance; Penmark Research model.
| Cross-check / reverse solve | Value |
|---|---|
| FY30E sales ($172.8m) × 2.35x peer EV | $406.1m |
| PV of FY30E exit (×0.6489x) | $263.5m |
| PV of after-tax FCF to FY30E | −$207.3m |
| PV of post-FY30E CR1 & SLS009 | $588.2m |
| Cross-check EV + $303.5m cash & raises | $948.0m |
| Cross-check value / share (−17.4%) | $4.11 |
| Value at 100% CR2 approval odds | $6.36 |
| Price-implied GPS sizing scalar | 3.44x |
| Implied US GPS peak (at $19.15) | $4,922.7m |
Source: Penmark Research model.
Source: Penmark Research model (base cell boxed at $4.97).
Source: Penmark Research model (base cell boxed at $4.97).
Why the peer exit cross-check sits 17.4% below primary rNPV
Capping FY30E launched GPS sales at the 2.35x peer median values SLS at $4.11/sh (−17.4% vs $4.97/sh). The $0.87/sh gap arises because a 2.35x sales multiple in launch year three prices mature competition and patent decay more harshly than our explicit discounted cash flow (DCF), which gives GPS 12-year biologic exclusivity to FY40E at ~85% gross-less-royalty margin.
Multiples at actual price vs target: At $19.15, SLS trades at 21.77x FY30E risk-adjusted sales ($172.8m) versus 10.12x at our $8.77 target, because CR1 and SLS009 cash flows begin only in FY31E–FY32E.
Reverse DCF / rNPV shows impossible implied volume
A reverse DCF (here reverse rNPV) solves backwards from today’s share price to find what operating performance the market is pricing in. Because 100% CR2 odds reach only $6.36/sh and the highest cell across both two-way grids is $8.08/sh, justifying $19.15 requires scaling CR2 and CR1 treated patients 3.44x to $4,923m peak US sales.
Discount-rate resilience: Cutting cost of equity by 200 bps to 9.1% alongside 65% CR2 uptake reaches $7.74/sh, still 60% below $19.15.
Probability-weighted scenarios roll forward to $8.77/sh (−54.2% return); zero tests flip Sell
| Scenario input / valuation output | Bear (30%) | Base (50%) | Bull (20%) | Weighted / Target |
|---|---|---|---|---|
| GPS CR2 approval probability | 40.0% | 65.0% | 85.0% | 61.5% eff. |
| US CR2 launch year & transplant-ineligible share | FY29E / 50% | FY28E / 60% | FY28E / 70% | n.a. |
| GPS US net price / patient-yr | $200k | $300k | $450k | $300k wtd |
| CR2 peak penetration & mean treatment duration | 30% / 1.00y | 45% / 1.25y | 70% / 1.75y | n.a. |
| GPS CR1 approval odds & CR1 peak penetration | 15% / 10% | 30% / 20% | 50% / 35% | n.a. |
| SLS009 / tambiciclib approval odds | 8.0% | 13.0% | 25.0% | n.a. |
| Present value per share at price date (17 Nov 2026) | $0.18 | $4.97 | $26.77 | $7.90 |
| Return to present value vs $19.15 close | −99.0% | −74.0% | +39.8% | −58.8% |
| 12m roll-forward at 11.06% CoE ($0 dividends/sh, DPS) | $0.21 | $5.52 | $29.73 | $8.77 |
| 12-month total return vs $19.15 & implied rating | −98.9% (Sell) | −71.2% (Sell) | +55.2% (Buy) | −54.2% (Sell) |
Source: Penmark Research model ($7.8957 × 1.11056 = $8.7686/sh; zero expected dividends).
| Robustness test (holding other inputs at base) | Setting tested | Base rNPV ($/sh) | 12m rolled ($/sh) | vs $19.15 | Call |
|---|---|---|---|---|---|
| Sector-only biotech beta (Damodaran 496 firms) | Beta 1.08x (CoE 9.70%) | $5.57 | $6.11 | −68.1% | Sell |
| SLS 5-year monthly jump-driven regression beta | Beta 2.70x (CoE 16.57%) | $3.27 | $3.81 | −80.1% | Sell |
| Risk-free rate / cost of equity −200 bps | CoE 9.06% | $5.89 | $6.42 | −66.5% | Sell |
| Risk-free rate / cost of equity +200 bps | CoE 13.06% | $4.24 | $4.79 | −75.0% | Sell |
| GPS CR1 Phase 3 approval odds +15pp | CR1 odds 45.0% | $6.06 | $6.73 | −64.8% | Sell |
| GPS CR2 approval certainty (unrisked CR2) | CR2 odds 100.0% | $6.36 | $7.06 | −63.1% | Sell |
| Scenario weight needed to flip Sell to Hold (≥−10%) | Bull weight ~55% (Bear 30%) | n.a. | ~$17.24 | −10.0% | Threshold |
Source: Penmark Research model (0 robustness tests change our Sell rating).
Why the bear case sits below the cash floor
Our $0.18/sh bear value sits below the $1.19/sh cash floor because a weak self-launch does not cover the field force and corporate overhead. At $200k net pricing, 30% uptake and 1.0-year therapy delayed to FY29E, US gross profit falls short of the $45m–$60m sales force and ongoing G&A; partnering or cutting spend would leave more of the cash floor intact.
The scenario distribution is skewed upward toward the bull case. Scenario weights (30% / 50% / 20%) are judgemental probabilities set from the clinical and commercial debate evidence; the $26.77/sh bull case at 20% weight pulls the probability-weighted value to $7.90/sh, 59% above our $4.97/sh base.
Target derivation and valuation date
Rolling our $7.90/sh probability-weighted present value forward 12 months at the 11.1% cost of equity gives our $8.77/sh price target. With zero expected dividends, the 12-month total return matches the −54.2% price return, well below our −10% Sell threshold.
Valuation date & offering convention: All valuation outputs follow our model dated 19 Nov 2026 anchored to the 17 Nov 2026 official Nasdaq close of $19.15, and include $140.25m assumed net offering proceeds at $17.00/sh while excluding the $22.5m 30-day option.
Upcoming REGAL subgroup data, FDA pre-BLA minutes and deal pricing test our $8.77 target
Source: SEC filings and 17 Nov 2026 company release; Penmark Research estimates.
| Date & event | Driver watched | Penmark expectation | Market / Street view | Value impact |
|---|---|---|---|---|
| Nov 2026: $150m deal pricing | Equity dilution & share supply | $17.00/sh assumed; $140.25m net (+8.82m sh; $22.5m option unexercised) | Pricing not yet public ($16.61–$16.90 after-hours, −12%) | $0.00 (in base) |
| Dec 2026: ASH SLS009 & KOLs | GPS peak-sales & pipeline | 34% overall ORR; 54%–57% in monocytic & TP53 subsets (30 mg BIW) | $400k+ GPS net price & 60%+ CR2 uptake | +$0.16 / +$0.58 (indicative) |
| Dec 26–H1 27: Full REGAL data | REGAL survival & FDA odds | Subgroup, censoring & salvage-therapy detail; RFS secondary endpoint | Uniform OS benefit across prior-venetoclax & cytogenetic subsets | −$0.67 to +$0.40 (indicative) |
| H1 27: Pre-BLA & BLA filing | REGAL survival & FDA odds | BLA filed with post-marketing study commitment (65% approval odds) | Unconditional review (≥85% odds) | −$0.67 to +$0.40 (indicative) |
| 2027: SLS009 Ph2 & CR1 Ph3 | Equity dilution & share supply | 80-pt SLS009 readout; CR1 Ph3 starts ($110.2m FY27E spend vs $26m Street loss) | FY27E $53m sales & low burn | +$0.16 / +$0.36 (indicative) |
| FY2028E: FDA PDUFA & US launch | GPS peak-sales expectations | US CR2 launch at $300k net price; 20% year-1 ramp ($19.0m risk-adjusted revenue) | Consensus $122m FY28E sales | Bear $0.18 / Bull $26.77 |
Source: SEC filings; company releases; Penmark Research model (catalyst/risk impacts are indicative; Bear/Bull are full-model scenario values).
| Indicator | Thesis confirmed if (Sell holds) | Thesis broken if (review rating) |
|---|---|---|
| REGAL subgroups & FDA minutes | Subgroup attenuation (prior-venetoclax / cytogenetics), censoring or salvage imbalances, weak secondary RFS, or FDA request for a confirmatory trial | Consistent OS and secondary RFS benefit across venetoclax-exposed and cytogenetic subgroups, clean censoring, and unconditional BLA acceptance |
| GPS US net price & CR2 share | US net price settles near or below our $300k/yr base ($200k bear) and unfit CR2 share tracks ≤45% (~750–850 patients) | US net price clears the $400k/yr market view ($450k bull) alongside ≥70% bull-case CR2 penetration and 1.75-yr duration |
| FY27E–28E burn & partnerships | SELLAS self-funds FY27E BLA/CR1 Ph3 ($110.2m spend; FY27E sales unlikely) and FY28E US 60-rep launch ($97.2m EBITDA loss) | Non-dilutive pharma co-promotion or buyout eliminates standalone FY28E US field ($45m–$60m/yr) and CR1 trial spend ($95m) |
Source: Penmark Research monitoring framework derived from model assumptions and scenario thresholds.
M&A or elevated short interest pose upside risks to Sell; our bear case values SLS at $0.18
Source: Penmark Research model.
| Risk factor | Prob. | Value impact | Mechanism & analytical assessment |
|---|---|---|---|
| Upside risks against our Sell rating (bullish counter-evidence) | |||
| Multi-programme bull case | 20% | $26.77 bull case | 85% CR2 odds, $450k net price, 70% share, 1.75y stay, 50% CR1 & 25% SLS009 odds |
| KOL-led 60% CR2 uptake | 30% | +$0.58 (indicative) | Faster community adoption lifts peak unfit CR2 share from 45% to 60% |
| Strategic pharma buyout | Unmodelled | Unquantified | Acquirer with existing AML reps could avoid standalone US field & G&A; $3.90bn cap deters bids |
| Elevated short interest | Unmodelled | Trading risk | 57.13m shares short at 30 Oct (28.1% of 203.53m basic; 6.7d cover); 119.93m sh traded on 17 Nov |
| Fundamental downside risks (reinforcing Sell; full bear case = $0.18/sh at 30% weight) | |||
| FDA asks confirmatory Ph3 | 30% | −$0.67 (indicative) | Open-label 126-pt single trial (p=0.035; CI pending) cuts CR2 odds to 40% & FY29E launch |
| Menin / venetoclax & price cap | 25%–30% | −$0.58 each (indicative) | Targeted combos shrink unfit CR2 pool (30% share) or payers cap vaccine net price at $200k |
| Patent vs biologic cliff | Unmodelled | 59% GPS PV >2035 | Licensed composition patents expire 2034–35 vs 12-yr biologic exclusivity modelled to 2040 |
| CMC, 13 FTEs, China & legal | Unmodelled | Unquantified | Single-source CMOs, 13-FTE load, $191.5m excluded 3D milestones & Pomerantz inquiry |
Source: SEC filings; FINRA short-interest data; Penmark Research model (single-item risk figures are indicative; $26.77 and $0.18 are full-model scenario values).
What could challenge a Sell position
Elevated short interest and mergers & acquisitions (M&A) are the sharpest near-term upside hazards. With 57.13m shares short at the 30 Oct settlement (28.1% of basic shares) and a $150m offering resetting positioning, shares can stay detached from rNPV between ASH (Dec 2026) and BLA filing (H1 27).
Strategically, a large haematology incumbent could absorb GPS into an existing US sales force, avoiding $45m–$60m/yr of standalone field spend and $235.2m PV of corporate costs. Yet paying above $3.90bn ($3.76bn EV) for an unapproved CR2 vaccine (1,701 US patients) would strain acquirer return on invested capital (ROIC) unless CR1 is de-risked.
Regulatory, IP, key-person and governance risks
IP & regulatory: Our model grants GPS 12-year US biologic reference exclusivity to FY40E even though licensed MSK composition patents expire in 2034–2035 (heptavalent filings run to 2040); if peptide synthesis is challenged earlier, 59% of GPS (CR2 plus CR1) risk-adjusted present value sits after 2035 (46% for CR2 alone).
Operational & legal: Executing a BLA, commercial launch and two global trials with 13 employees and single-source CMOs (Polypeptide Group; PCI/LSNE) creates execution risk. Pomerantz LLP’s investor inquiry and Section 382 NOL limits remain unquantified.
Short interest reached 57.1m shares ahead of REGAL; 13F filers report 35.2% of shares
Source: Financial Industry Regulatory Authority (FINRA) short-interest settlements, Nov 2025 to 30 Oct 2026 (57.13m shares; 6.7d cover).
| Institution (Form 13F) | Shares (m) | % basic* | Q3 Δ (m) | Q3 Δ % |
|---|---|---|---|---|
| BlackRock, Inc. | 16.18 | 7.95% | +1.11 | +7.4% |
| The Vanguard Group | 13.01 | 6.39% | +0.99 | +8.2% |
| State Street Corp. | 10.37 | 5.10% | −2.62 | −20.2% |
| Geode Capital Mgmt | 5.17 | 2.54% | +0.29 | +5.9% |
| Susquehanna Intl Group | 2.64 | 1.30% | +0.59 | +28.7% |
| Northern Trust Corp. | 1.85 | 0.91% | +0.23 | +14.3% |
| Charles Schwab Inv. Mgmt | 1.80 | 0.88% | +1.24 | +218.9% |
| Morgan Stanley | 1.51 | 0.74% | +0.27 | +22.2% |
| UBS Group AG | 1.49 | 0.73% | +0.23 | +18.6% |
| DAGCO, Inc. | 1.34 | 0.66% | +0.10 | +8.4% |
| All reported 13F filers | 71.54 | 35.15% | −1.81 | −2.5% |
*Partial 13F coverage (71.54m of 203.53m basic shares; not a complete ownership census). Source: SEC Form 13F filings (Q2–Q3 2026).
| Trading & liquidity item | Reading | Street & capital overhang item | Reading |
|---|---|---|---|
| 17 Nov 2026 official valuation close | $19.15 | Named Street ratings (Buy / Hold / Sell) | 2 / 0 / 0 |
| 52-week intraday low – high (to 17 Nov) | $1.39 – $24.89 | Street targets (Maxim $40; AGP $35; mean) | $37.50 |
| 17 Nov REGAL event-day volume | 119.93m sh | Proposed 17 Nov offering + 30-day option | $150m + $22.5m |
| 3M avg daily value (incl. / excl. 17 Nov) | $114.0m / $80.4m | Unused ATM equity shelf capacity | $150.0m |
| FINRA short interest (30 Oct; % basic) | 57.13m (28.1%) | Warrants ($2.07 strike) & options ($3.21) | 8.12m & 2.65m |
| Insiders & directors (15 Apr proxy) | 2.42m (1.3%) | 2023 Equity Plan addition (Jun 2026 vote) | +20.00m sh |
Source: Yahoo Finance; FINRA short-interest data; SEC Form 4, DEF 14A (Apr 2026) and Q3 2026 Form 10-Q filings; Penmark Research model.
Passive index giants and retail dominate trading
Reported 13F institutional filings cover only 35.2% of 203.53m basic shares, led by passive index trackers. BlackRock (8.0%), Vanguard (6.4%), State Street (5.1%) and Geode (2.5%) hold over three-fifths of reported 13F stock, leaving non-13F retail and fast-money traders setting marginal prices.
Short interest rose from 31.8m to 57.1m shares (28.1% of basic shares) over the 12 months to 30 Oct. Following the 17 Nov REGAL topline announcement, 119.9m shares (~59% of basic shares) traded in a single session.
Heavy equity overhangs and grant-based insider holdings
Insiders hold 1.3% beneficially via equity grants rather than open-market cash purchases. Form 4 records reflect compensation awards (such as CEO Stergiou’s 1.07m-share June 2026 grant) with no recent open-market insider buying or selling.
Substantial share supply sits overhead. Alongside the proposed $150m underwritten offering (plus $22.5m option), SELLAS retains an unused $150m ATM shelf, 8.12m in-the-money warrants ($2.07 average strike) and 20.0m newly authorised employee plan shares.
Summary statements, programme rNPV & quarterly history from FY24A through FY35E
| Line item | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY32E | FY35E |
|---|---|---|---|---|---|---|---|---|---|
| Income statement & per-share metrics | |||||||||
| Revenue (risk-adjusted) | $0.0 | $0.0 | $0.0 | $0.0 | $19.0 | $107.8 | $172.8 | $270.6 | $563.3 |
| Memo: GPS CR2 US sales (unrisked) | $0.0 | $0.0 | $0.0 | $0.0 | $29.3 | $165.9 | $264.2 | $329.8 | $360.6 |
| Operating costs (incl. SBC) | −$31.5 | −$28.3 | −$45.2 | −$110.2 | −$116.2 | −$125.6 | −$135.4 | −$120.1 | −$170.7 |
| EBITDA (risk-adjusted) | −$31.5 | −$28.3 | −$45.2 | −$110.2 | −$97.2 | −$17.7 | $37.4 | $150.5 | $392.6 |
| EBITDA margin (%) | n.m. | n.m. | n.m. | n.m. | −510.6% | −16.4% | 21.6% | 55.6% | 69.7% |
| Net interest / other income | $0.6 | $1.4 | $4.3 | $9.2 | $5.6 | $2.6 | $2.6 | $6.7 | $28.7 |
| Cash income tax (24% post-NOL) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | −$1.8 | −$7.2 | −$94.2 |
| Net income | −$30.9 | −$26.9 | −$40.9 | −$101.0 | −$91.5 | −$15.1 | $38.2 | $150.0 | $327.1 |
| Shares (wtd actuals; YE forecasts, m) | 61.2 | 109.1 | 212.4 | 212.4 | 213.8 | 218.1 | 218.1 | 218.1 | 218.1 |
| Diluted EPS ($/sh; $0.00 DPS) | −$0.50 | −$0.25 | −$0.19 | −$0.48 | −$0.43 | −$0.07 | $0.18 | $0.69 | $1.50 |
| Cash flow, liquidity & balance-sheet metrics ($0.0m debt throughout) | |||||||||
| Working capital change | −$4.5 | −$1.5 | $5.7 | $0.0 | −$2.9 | −$13.3 | −$9.6 | −$7.2 | −$8.1 |
| Free cash flow (incl. interest) | −$35.4 | −$28.4 | −$35.2 | −$101.0 | −$94.4 | −$28.4 | $28.6 | $142.7 | $319.0 |
| Net equity raised (cash roll) | $46.8 | $86.3 | $140.3* | $0.0 | $8.3 | $28.4 | $0.0 | $0.0 | $0.0 |
| Year-end cash & equivalents | $13.9 | $71.8 | $262.1 | $161.1 | $75.0 | $75.0 | $103.6 | $334.5 | $1,139.3 |
*FY26E cash roll starts at 30 Sep 2026 ($134.7m cash; 9M26A included $85.3m of warrant/financing inflows) plus $140.25m assumed Nov offering. Source: SEC filings; Penmark Research model.
| Programme / corporate block | 2026 US pool | Launch / cliff | Approval odds | Peak share / price | Unrisked US peak | Risked peak rev. | PV ($m) | PV ($/sh) |
|---|---|---|---|---|---|---|---|---|
| GPS AML CR2 maintenance (REGAL) | 1,701 pts | FY28E / FY40E | 65.0% | 45% / $300k | $418.5m | $287.4m | $698.8 | $3.03 |
| GPS AML CR1 expansion (Ph3) | 7,718 pts | FY32E / FY40E | 30.0% | 20% / $300k | $1,012.6m | $320.9m | $574.4 | $2.49 |
| SLS009 / tambiciclib (r/r + 1L AML) | 6,300 pts | FY31E / FY41E | 13.0% | 30% / $250k | $401.2m | $55.1m | $89.7 | $0.39 |
| Corporate G&A + cash taxes (post-NOL) | n.a. | FY26E–FY45E | 100% / 24% | n.a. | n.a. | n.a. | −$518.2 | −$2.24 |
| Enterprise rNPV + $303.5m cash & raises | 15,719* | Zero terminal | 11.06% CoE | 230.85m sh | $1,832.2m | $661.8m** | $1,148.2 | $4.97 |
*CR1/CR2 overlap not modelled. **Coincident FY40E company peak ($53.5m SLS009 in FY40E vs $55.1m FY41E peak). Source: Penmark Research model.
| GAAP quarterly line | 1Q25A | 2Q25A | 3Q25A | 4Q25A* | 1Q26A | 2Q26A | 3Q26A | 9M26A |
|---|---|---|---|---|---|---|---|---|
| Research & development (R&D) | $3.21 | $3.87 | $4.22 | $4.73 | $5.13 | $6.27 | $7.03 | $18.43 |
| General & administrative (G&A) | $2.86 | $3.00 | $2.87 | $3.53 | $4.12 | $4.36 | $4.28 | $12.76 |
| Operating loss ($0.00m revenue) | −$6.06 | −$6.87 | −$7.08 | −$8.26 | −$9.25 | −$10.63 | −$11.31 | −$31.19 |
| Net loss (after treasury interest) | −$5.81 | −$6.60 | −$6.79 | −$7.66 | −$8.41 | −$9.61 | −$10.09 | −$28.10 |
| Basic & diluted EPS ($/sh) / wtd sh (m) | −$0.07 (88m) | −$0.07 (99m) | −$0.06 (108m) | n.a. | −$0.05 (172m) | −$0.05 (189m) | −$0.05 (202m) | −$0.15 (188m) |
*4Q25A = FY25A less 9M25A. Return on equity (ROE), return on assets (ROA) and return on capital employed (ROCE) are n.m. while earnings are negative through FY29E. Source: SEC Form 10-K and Form 10-Q filings.
Six-company peer set, glossary, methodology notes & primary data sources
| Peer (ticker) | Lead marketed asset & comparability rationale | Mkt cap | EV | EV/sales | Rev. y/y |
|---|---|---|---|---|---|
| Syndax (SNDX) | Revuforj (menin inhibitor in r/r AML) & Niktimvo; US commercial haematology build | $825.6m | $642.7m | 1.93x | +81.6% |
| Kura (KURA) | Komzifti (ziftomenib, NPM1-m r/r AML); targeted US AML launch benchmark | $672.7m | $190.5m | 2.08x | +10.1% |
| Immunocore (IMCR) | Kimmtrak (TCR biologic in uveal melanoma); orphan immunotherapy benchmark | $1,432.8m | $926.3m | 2.27x | −1.4% |
| Rigel (RIGL) | Rezlidhia (IDH1-m r/r AML), Tavalisse, Gavreto; niche haematology sales force | $879.6m | $787.5m | 2.43x | +16.5% |
| Geron (GERN)* | Rytelo (imetelstat in MDS/myeloid); *EV overstated (marketable securities omitted) | $680.8m | $732.1m | 3.04x | +27.4% |
| Iovance (IOVA) | Amtagvi (TIL cell therapy); single-asset US oncology immunotherapy launch | $3,437.6m | $3,061.3m | 6.30x | +80.1% |
Source: SEC Q3 2026 Form 10-Q filings; Yahoo Finance; Penmark Research model.
| Term / ratio | Plain-English definition & report convention |
|---|---|
| AML & CR1 / CR2 | Acute myeloid leukaemia; first (CR1) or second (CR2) morphologic bone-marrow remission (<5% blasts) after therapy. |
| GPS & WT1 | Galinpepimut-S, investigational 4-peptide vaccine licensed from MSK targeting Wilms tumour-1 (WT1) nuclear antigen. |
| SLS009 (tambiciclib) | Selective small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed ex-Greater China from GenFleet. |
| OS, RFS, HR & ORR | Overall survival; relapse-free survival; hazard ratio (HR 0.59 = 41% lower hazard of death); overall response rate. |
| BLA & rNPV | Biologics License Application to FDA; risk-adjusted net present value (post-approval cash flows × odds, less pre-approval R&D). |
| GAAP vs adjusted | SELLAS reports GAAP figures only (no non-GAAP adjustments); stock-based compensation ($1.96m FY25A) is treated as a real cost. |
| EV / run-rate sales | Enterprise value (market cap − cash & ST investments + debt) divided by FQ3 2026 revenue × 4 (or FY30E risk-adjusted revenue for SLS). |
| Cash floor per share | 30 Sep 2026 cash ($134.71m) plus assumed Nov offering net proceeds ($140.25m) divided by 230.85m diluted shares = $1.19/sh. |
Source: SEC filings; Penmark Research model.
Methodology, date & scope caveats
Archetype & valuation date: SELLAS is modelled under our pre-revenue pipeline biotech framework using explicit programme-level rNPV. This report and our valuation model are dated 19 November 2026 and anchored to the official 17 November 2026 Nasdaq close of $19.15/sh.
Offering & clinical caveats: The proposed $150m underwritten offering announced after the 17 Nov close had not priced as of 19 Nov 2026; we include $140.25m of assumed net proceeds at $17.00/sh and exclude the $22.5m 30-day option until exercised. GPS remains investigational: positive open-label single-trial REGAL topline results do not guarantee FDA approval, and 95% confidence intervals, survival curves and secondary endpoints remain pending.
Unmodelled items: Excludes $191.5m 3D Medicines China milestones and unquantified Pomerantz LLP investor inquiry; ignores CR1/CR2 patient overlap and Section 382 NOL caps; approximates tax on probability-weighted income; models 12-year biologic exclusivity to 2040 vs composition patents expiring 2034–2035.
Primary data sources & coverage limits
Filings & company releases: SEC Form 10-K for FY2025 (filed 19 Mar 2026), Form 10-Q for Q3 2026 (ended 30 Sep 2026, filed 12 Nov 2026), DEF 14A proxy (filed Apr 2026), Form 8-K annual meeting vote (Jun 2026), and company releases dated 28 Oct, 4 Nov and 17 Nov 2026 via SEC EDGAR and company investor relations.
Market, ownership & call limits: Share prices, intraday 52-week ranges, volumes and index returns (XBI, S&P 500) come from Yahoo Finance through 17 Nov 2026. Short-interest settlements (to 30 Oct 2026) come from FINRA; Form 4 insider awards and Form 13F holdings (to 30 Sep 2026; partial 35.2% coverage of 203.53m basic shares) come from SEC filings. SELLAS holds no quarterly earnings calls.
Benchmarks & consensus: Clinical transition base rates come from BIO/Informa/QLS all-indication data (2011–2020); equity risk premium comes from Damodaran implied ERP, 1 May 2026 (4.24%), alongside Damodaran’s US biotech beta (1.08x). Pre-REGAL revenue and earnings estimates come from Simply Wall St and Seeking Alpha; Street price targets come from Maxim Group ($40, raised from $30 on 17 Nov 2026) and Alliance Global Partners ($35, raised from $25 in Oct–Nov 2026).
Analyst certification and important disclosures
Ratings
Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Total return to price target above +10% |
| Hold | Total return to price target from −10% to +10%, inclusive |
| Sell | Total return to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.